Analysis of the APAC Cardiac Troponin Diagnostics Market, Forecast to 2021
Analysis of the APAC Cardiac Troponin Diagnostics Market, Forecast to 2021
Increasing Incidence Rates of Myocardial Infarction and Aging Population in APAC Drive the Troponin Diagnostics Market
16-Apr-2018
Asia Pacific
Description
Cardiac troponins will continue to remain the gold standard for early diagnosis of acute myocardial infarction (AMI); however, the key challenge to address is the advent of a complementary biomarker to prevent repeat diagnosis. Multiplexing platforms should be harnessed for simultaneous testing of complementary biomarkers such as H-FABP, cardiac myosin binding C protein, co-peptin, and Pentraxin 3 (PTX3) that should be combined with utmost clinical utility. Chinese Food & Drug Administration (CFDA) and regional market access to APAC countries such as Indonesia and India will emerge as key markets with early commercial access with the new proposed CE regulatory guidelines that require lengthy approval times and clinical benefits. Furthermore, with the huge market opportunities in emerging APAC countries, unlike the conventional approach APAC market, access will take a center stage in parallel with Europe and the US.
There is a general trend toward decentralization of laboratory testing in hospitals that have demonstrated an overall improvement in operational efficiency by 30% to 40%, further supported by the overall trends in pathology price cuts as an indirect measure to rising healthcare expenditure. Given the overall market trends in central lab testing, there will be a higher propensity toward adoption of POCT, with quantitative outcomes for mainstream clinical diagnosis. There will be an increase in adoption of POCT, which would eventually shrink the lab-based market for troponin biomarkers used for the diagnosis of MI.
Physicians are demanding for a more accurate test which could reduce the burden in the healthcare settings. For patients under the acute critical conditions such as myocardial infarction, fast results and quick diagnosis are required. The rising prevalence of MI and increasing morbidity in the region will fuel the growth of diagnostic testings. Moreover, demands from physicians for more accurate and sensitive results will push researchers and investments for the diagnosis of MI.
Key Issues Addressed
- What are the key healthcare trends that could impact the APAC cardiac biomarker diagnostics market?
- What are the market drivers and restraints that are impacting the market growth?
- What are the unmet needs and the opportunities for the existing and emerging participants?
- What are the segment shares of the key market participants?
- How are companies dealing with the challenges in the market space?
- What are the future trends and the forecast scenario of the AMI biomarkers diagnostics in a different region?
RESEARCH: INFOGRAPHIC
This infographic presents a brief overview of the research, and highlights the key topics discussed in it.Click image to view it in full size
Table of Contents
Key Findings
Key Findings (Continued)
Scope and Segmentation
Key Questions This Study Will Answer
Market Engineering Measurements
Key Companies to Watch
Market Background
Cardiac Diagnostics Market Overview
Cardiac Biomarker Diagnostics Overview
Cardiac Diagnostics Overview
Market Overview—Testing Procedure
Defining Healthcare Trends in the Future
New Market Opportunities
Competitive Structures
Notable Deals and Launches—Cardiac Biomarker Diagnostics
Market Drivers
Drivers Explained
Drivers Explained (continued)
Market Restraints
Restraints Explained
Restraints Explained (continued)
Forecast Methodology
Market Engineering Measurements
Revenue Forecast
Revenue Forecast Discussion
Percent Revenue Forecast Breakdown by Segments
Market Share
Market Share Analysis
Major Growth Opportunities
Growth Opportunity Matrix
Growth Opportunity 1—Companion Diagnostics
Growth Opportunity 2—POCT in Cardiac Biomarker Diagnostics
Growth Opportunity 3—Integrated and Efficient System
Growth Opportunity 4—Digital Health and Diagnostics Inter-convergence Model
Strategic Imperative for Cardiac Troponins Market
Market Engineering Measurements
Revenue Forecast
Revenue Forecast Discussion
Segment Share
Segment Share Analysis
Market Engineering Measurements
Revenue Forecast
Revenue Forecast Discussion
Segment Share
Segment Share Analysis
The Last Word—3 Big Predictions
Legal Disclaimer
List of Exhibits
List of Exhibits (continued)
List of Others Companies
Market Engineering Methodology
The Frost & Sullivan Story
Value Proposition—Future of Your Company & Career
Global Perspective
Industry Convergence
360º Research Perspective
Implementation Excellence
Our Blue Ocean Strategy
Related Research
Popular Topics
No Index | No |
---|---|
Podcast | No |
Author | Nitin Naik |
Industries | Healthcare |
WIP Number | P9F1-01-00-00-00 |
Keyword 1 | Cardiac Troponin |
Is Prebook | No |
GPS Codes | 9600-B1,9611-B1,9627-B1,99C1-B1,99C6-B1,9A43-B1,9A4E-B1,9A50-B1 |